NIH Proteomics Interest Group

Link to Upcoming Meetings

Link to Meeting Archives

Link to Related Links

Link to NIH Labs

Link Fellows Forum Info

Link to Join SIG


ProtIG is an NIH Special Interest Group (SIG) that organizes seminars and workshops in relevant areas of proteomics, including talks on separation and protein identification methods, determination of post-translational modifications, protein-protein interactions, and bioinformatics and data management. A monthly seminar series is held at 10am usually on the first Thursday of each month (always check the Mtgs/Seminars button on this page for these and other PROTIG announced meetings). To receive email announcements of ProtIG events, join the listserv (Join the SIG button on this page)
Please note the location for this seminar is in Building 50.

April ProtIG Seminar
April 3rd, 2014
10:00am - 11:00pm
Building 50, NIH Campus
Room 1227/1233
Josip Blonder, M.D.
Cancer Research Technology Program
Frederick National Laboratory for Cancer Research
Leidos Biomedical Research, Inc.

"Towards Cancer Biomarker Discovery Using Clinical MS-based Proteomics"

Cancer biology and clinical oncology are undergoing rapid transformation, specifically from an organ-centric to a molecular pathways focused disciplines. Data obtained from cancer cell lines and/or animal models are not always predictive of what is actually happening in human cancers in vivo. Hence, mass-spectrometry (MS)-based proteomics of clinical specimens plays important role in cancer biomarker research because of its capability to directly measure gene end-products within a tumor micro-environment. However, despite advances in cancer biomarker research, the translation of proteomic methods and findings to applicable clinical assays has been disappointing. Principal factors that hinder (MS)-based biomarker research include (i) significant heterogeneity of solid tumors, (ii) formidable variability of protein expression in the human population proper, (iii) huge dynamic range of human plasma protein expression (i.e., >10 orders of magnitude), (iv) the 22 most abundant blood-derived proteins constitute approximately 99% of the total plasma protein mass, (v) substantial amounts of highly abundant blood-derived proteins found in intestinal fluid and tissue-embedded networks of blood and lymph capillaries, (vi) considerable mismatches between the dynamic range of current MS instrumentation and the dynamic range of protein content in clinical specimens, and (vii) the majority of validated proteomics-derived “potential” cancer biomarkers were not germane to the tumor in question. In addition, the poor experimental design of early ‘proof-of-principle’ studies relying mostly on plasma/serum and low-resolution MS instrumentation have not been beneficial to the field of clinical proteomics. This presentation focuses on our progress in solving technological barriers interfering with MS-based profiling of clinical specimens. The present strategy/pipeline may accelerate translation of proteomic findings into novel cancer biomarker and/or MS-based clinical tests.

Please remember everyone is welcome to join us for the Fellows Forum Seminar on the 19th of March (in Building 10, Room 5-2250) where M. Brad Strader [FDA] will present. See the Fellows Forum for more information.

NIH Special Interest Groups home page NIH Home Page

This site was updated on March 11th, 2014. Please contact Renee Olano at olanol(at) with questions or suggestions.